Search research articles
Contact Us
Filters
Showing results (11-20 of 33) with videos related to
Page
of 4
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
December 18, 2020
Prognostic implications of dual tracer PET/CT: PSMA ligand and [<sup>18</sup>F]FDG PET/CT in patients undergoing [<sup>177</sup>Lu]PSMA radioligand therapy
Kerstin Michalski, Juri Ruf, Christian Goetz, et al.
Nuclear Medicine and Biology
|
May 31, 2020
Association between gastrin-releasing peptide receptor expression as assessed with [<sup>68</sup>Ga]Ga-RM2 PET/CT and histopathological tumor regression after neoadjuvant chemotherapy in primary breast cancer
Kerstin Michalski, Christian Stoykow, Peter Bronsert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 27, 2022
Prognostic Value of Tumor Volume Assessment on PSMA PET After <sup>177</sup>Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0
Felix Kind, Ann-Christin Eder, Cordula A Jilg, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
May 17, 2023
PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort
Alexander Brose, Kerstin Michalski, Juri Ruf, et al.
Molecular Imaging and Biology
|
February 9, 2024
Volumetric Parameters Derived from CXCR4-Directed PET/CT Predict Outcome in Patients with Gastrointestinal Neuroendocrine Carcinomas
Kerstin Michalski, Wiebke Schlötelburg, Philipp Hartrampf, et al.
Annals of Nuclear Medicine
|
October 27, 2023
Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy
Kerstin Michalski, Aleksander Kosmala, Rudolf A Werner, et al.
Clinical Nuclear Medicine
|
May 27, 2020
Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT
Kerstin Michalski, Katharina Laubner, Christian Stoykow, et al.
Cancers
|
September 10, 2021
Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [<sup>177</sup>Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome
Philipp E Hartrampf, Constantin Lapa, Sebastian E Serfling, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 18, 2026
Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapy
Song Xue, Sabrina Kraus, Johanna S Enke, et al.
Frontiers in Nuclear Medicine
|
April 27, 2026
Prognostic impact of discordant lesions on [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT compared to histological FAP expression in neuroendocrine neoplasms
Tim Jedamzik, Aleksander Kosmala, Stefan Kircher, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 33) with videos related to
Sort By:
Page
of 4
European Journal of Nuclear Medicine and Molecular Imaging
|
December 18, 2020
Prognostic implications of dual tracer PET/CT: PSMA ligand and [<sup>18</sup>F]FDG PET/CT in patients undergoing [<sup>177</sup>Lu]PSMA radioligand therapy
Kerstin Michalski, Juri Ruf, Christian Goetz, et al.
Nuclear Medicine and Biology
|
May 31, 2020
Association between gastrin-releasing peptide receptor expression as assessed with [<sup>68</sup>Ga]Ga-RM2 PET/CT and histopathological tumor regression after neoadjuvant chemotherapy in primary breast cancer
Kerstin Michalski, Christian Stoykow, Peter Bronsert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 27, 2022
Prognostic Value of Tumor Volume Assessment on PSMA PET After <sup>177</sup>Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0
Felix Kind, Ann-Christin Eder, Cordula A Jilg, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
May 17, 2023
PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort
Alexander Brose, Kerstin Michalski, Juri Ruf, et al.
Molecular Imaging and Biology
|
February 9, 2024
Volumetric Parameters Derived from CXCR4-Directed PET/CT Predict Outcome in Patients with Gastrointestinal Neuroendocrine Carcinomas
Kerstin Michalski, Wiebke Schlötelburg, Philipp Hartrampf, et al.
Annals of Nuclear Medicine
|
October 27, 2023
Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy
Kerstin Michalski, Aleksander Kosmala, Rudolf A Werner, et al.
Clinical Nuclear Medicine
|
May 27, 2020
Detection of Insulinomas Using Dual-Time-Point 68Ga-DOTA-Exendin 4 PET/CT
Kerstin Michalski, Katharina Laubner, Christian Stoykow, et al.
Cancers
|
September 10, 2021
Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [<sup>177</sup>Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome
Philipp E Hartrampf, Constantin Lapa, Sebastian E Serfling, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 18, 2026
Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapy
Song Xue, Sabrina Kraus, Johanna S Enke, et al.
Frontiers in Nuclear Medicine
|
April 27, 2026
Prognostic impact of discordant lesions on [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT compared to histological FAP expression in neuroendocrine neoplasms
Tim Jedamzik, Aleksander Kosmala, Stefan Kircher, et al.
Page
of 4